{
  "content": "Patient Name: John Smith, MRN: 123456, DOB: 01/15/1960\n\nDiagnosis: Adenocarcinoma of the lung, stage IIIA (T4N0M0), diagnosed November 2021. No evidence of recurrence from prior malignancy.\n\nMolecular Profile: EGFR mutation positive (exon 19 deletion, VAF 45%), TMB-low (3.2 mut/Mb), MSI-stable, PDL1 expression 10%, ALK fusion negative.\n\nCurrent Status: Progressive disease on recent CT (12/2024) with new liver metastases and increasing primary mass. Shortness of breath worsening over past 2 weeks. Weight loss of 5kg. Performance status ECOG 1.\n\nComorbidities: Type 2 diabetes (well-controlled), ex-smoker (20 pack-years, quit 2019).\n\nPrior Treatment: Completed concurrent chemoradiotherapy (carboplatin/pemetrexed + 60Gy) March 2022 with partial response. Stopped maintenance pemetrexed October 2024 due to fatigue.\n\nMDM Plan:\nStart osimertinib 80mg daily\nRepeat CT chest/abdomen in 8 weeks\nConsider clinical trial enrollment if progression on osimertinib\nPalliative care referral for symptom management",
  "output": {
    "document_has_primary_cancer_flag": true,
    "primary_cancer_confirmed_flag": true,
    "primary_cancer": {
      "primary_cancer_facts": {
        "topography": "lung",
        "topography_name_desc": "lung",
        "morphology": "adenocarcinoma",
        "morphology_name_desc": "Adenocarcinoma",
        "is_recurrence": false,
        "diagnosis_year": 2021,
        "diagnosis_month": 11,
        "tnm_stage": "T4N0M0",
        "numeric_group_stage": "IIIA"
      },
      "primary_cancer_tumour_facts": {
        "msi_status": "ms_stable",
        "msi_desc": "MSI-stable",
        "tmb_status": "tmb_low",
        "tmb_numeric_value": 3.2,
        "tmb_desc": "TMB-low (3.2 mut/Mb)",
        "molecular_biomarker_profiles": [
          {
            "biomarker": "egfr",
            "biomarker_name_desc": "EGFR",
            "biomarker_status": "altered",
            "biomarker_alteration": "exon 19 deletion",
            "biomarker_expression_level": null,
            "biomarker_vaf_numeric_value": 45,
            "biomarker_vaf_desc": "VAF 45%",
            "biomarker_desc": "EGFR mutation positive (exon 19 deletion, VAF 45%)"
          },
          {
            "biomarker": "pdl1",
            "biomarker_name_desc": "PDL1",
            "biomarker_status": "altered",
            "biomarker_alteration": null,
            "biomarker_expression_level": "10%",
            "biomarker_vaf_numeric_value": null,
            "biomarker_vaf_desc": null,
            "biomarker_desc": "PDL1 expression 10%"
          },
          {
            "biomarker": "alk",
            "biomarker_name_desc": "ALK",
            "biomarker_status": "negative",
            "biomarker_alteration": null,
            "biomarker_expression_level": null,
            "biomarker_vaf_numeric_value": null,
            "biomarker_vaf_desc": null,
            "biomarker_desc": "ALK fusion negative"
          }
        ]
      },
      "primary_cancer_scores": null,
      "primary_cancer_spread": [
        {
          "spread_type": "liver",
          "spread_site_desc": "liver metastases"
        }
      ],
      "primary_cancer_timeline_events": [
        {
          "event_type": "had_systemic_or_radiotherapy_treatment",
          "event_year": 2022,
          "event_month": 3,
          "event_summary": "Completed concurrent chemoradiotherapy with partial response",
          "event_desc": "Completed concurrent chemoradiotherapy (carboplatin/pemetrexed + 60Gy) March 2022 with partial response"
        },
        {
          "event_type": "experienced_treatment_reduction_or_stop",
          "event_year": 2024,
          "event_month": 10,
          "event_summary": "Stopped maintenance pemetrexed due to fatigue",
          "event_desc": "Stopped maintenance pemetrexed October 2024 due to fatigue"
        },
        {
          "event_type": "radiology_evidence_of_disease_progression",
          "event_year": 2024,
          "event_month": 12,
          "event_summary": "Progressive disease on CT with new liver metastases",
          "event_desc": "Progressive disease on recent CT (12/2024) with new liver metastases and increasing primary mass"
        }
      ]
    },
    "performance_status": {
      "ps_scale": "ECOG",
      "ps_score_value": "1",
      "ps_desc": "Performance status ECOG 1"
    },
    "other_cancers": null,
    "patient_findings": [
      {
        "patient_finding_type": "symptom_finding",
        "patient_finding_name_desc": "Shortness of breath",
        "patient_finding_desc": "Shortness of breath worsening over past 2 weeks",
        "patient_finding_status": "is_present"
      },
      {
        "patient_finding_type": "symptom_finding",
        "patient_finding_name_desc": "Weight loss",
        "patient_finding_desc": "Weight loss of 5kg",
        "patient_finding_status": "is_present"
      },
      {
        "patient_finding_type": "comorbidity_finding",
        "patient_finding_name_desc": "Type 2 diabetes",
        "patient_finding_desc": "Type 2 diabetes (well-controlled)",
        "patient_finding_status": "is_present"
      },
      {
        "patient_finding_type": "social_or_family_finding",
        "patient_finding_name_desc": "Smoking history",
        "patient_finding_desc": "ex-smoker (20 pack-years, quit 2019)",
        "patient_finding_status": "is_present"
      }
    ],
    "future_plans": [
      {
        "future_plan_type": "planned_systemic_or_radiotherapy_treatment",
        "future_plan_summary": "Start osimertinib 80mg daily",
        "future_plan_desc": "Start osimertinib 80mg daily"
      },
      {
        "future_plan_type": "planned_investigation",
        "future_plan_summary": "Repeat CT chest/abdomen in 8 weeks",
        "future_plan_desc": "Repeat CT chest/abdomen in 8 weeks"
      },
      {
        "future_plan_type": "planned_clinical_trial_involvement",
        "future_plan_summary": "Consider clinical trial if progression on osimertinib",
        "future_plan_desc": "Consider clinical trial enrollment if progression on osimertinib"
      }
    ],
    "context_summary": {
      "doc_context": "MDM note",
      "doc_summary": "Patient with stage IIIA lung adenocarcinoma showing progression after chemoradiotherapy, now starting targeted therapy with osimertinib"
    }
  }
}
